SAB Corporate Presentation March 10, 2026 ATTD-2026 - Breaking the Depletion Paradigm: Immunomodulation Without Sustained Lymphodepletion with SAB-142, a Fully Human, Multi-Specific Anti-Thymocyte Globulin for T1D March 14, 2026 ATTD-2026 - Decoding the Binding Landscape for Multi-Specific T1D Biologics: Targeted Binding of Rabbit vs Human Anti-Thymocyte Globulin, SAB-142 March 12, 2026 ATTD-2026 - Charting the Safety Landscape of Multi-Specific Modalities: Safety Profile of Multi-Specific Anti-Thymocyte Globulin SAB-142 March 12, 2026 ATTD-2026 - Improving the Integrity of Clinical Samples: Assessing Blood Preservation Methods for Analysis by Flow Cytometry March 11, 2026 ATTD-2026 - Tracking Multiplicity: In Vitro and Clinical Pharmacokinetic Assays for Multi-Target Therapeutics March 11, 2026 ATTD-2026 - Beta Cell Guardians: Mechanism of Action of SAB-142, an Emerging Immunotherapy for New Onset T1D March 11, 2026 ATTD-Asia 2025 - Safety Profile of SAB-142 A Fully Human Anti-Thymocyte Globulin December 10, 2025 ATTD-Asia 2025 - Mechanism of Action of hATG December 10, 2025 ATTD-Asia 2025 - Immunomodulation without depletion December 10, 2025 ISPAD 2025 Conference - ePOSTER Safety Profile of SAB-142 A Fully Human Anti-Thymocyte Globulin November 7, 2025
ATTD-2026 - Breaking the Depletion Paradigm: Immunomodulation Without Sustained Lymphodepletion with SAB-142, a Fully Human, Multi-Specific Anti-Thymocyte Globulin for T1D March 14, 2026
ATTD-2026 - Decoding the Binding Landscape for Multi-Specific T1D Biologics: Targeted Binding of Rabbit vs Human Anti-Thymocyte Globulin, SAB-142 March 12, 2026
ATTD-2026 - Charting the Safety Landscape of Multi-Specific Modalities: Safety Profile of Multi-Specific Anti-Thymocyte Globulin SAB-142 March 12, 2026
ATTD-2026 - Improving the Integrity of Clinical Samples: Assessing Blood Preservation Methods for Analysis by Flow Cytometry March 11, 2026
ATTD-2026 - Tracking Multiplicity: In Vitro and Clinical Pharmacokinetic Assays for Multi-Target Therapeutics March 11, 2026
ATTD-2026 - Beta Cell Guardians: Mechanism of Action of SAB-142, an Emerging Immunotherapy for New Onset T1D March 11, 2026
ISPAD 2025 Conference - ePOSTER Safety Profile of SAB-142 A Fully Human Anti-Thymocyte Globulin November 7, 2025
